- Home
- AS vs GMAB Comparison
AS vs GMAB Comparison
Compare AS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AS
- GMAB
- Stock Information
- Founded
- AS 1950
- GMAB 1999
- Country
- AS Finland
- GMAB Denmark
- Employees
- AS N/A
- GMAB N/A
- Industry
- AS
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AS
- GMAB Health Care
- Exchange
- AS NYSE
- GMAB Nasdaq
- Market Cap
- AS 13.3B
- GMAB 12.1B
- IPO Year
- AS 2024
- GMAB N/A
- Fundamental
- Price
- AS $28.59
- GMAB $22.34
- Analyst Decision
- AS Buy
- GMAB Buy
- Analyst Count
- AS 14
- GMAB 9
- Target Price
- AS $26.07
- GMAB $40.71
- AVG Volume (30 Days)
- AS 2.8M
- GMAB 1.9M
- Earning Date
- AS 02-25-2025
- GMAB 02-12-2025
- Dividend Yield
- AS N/A
- GMAB N/A
- EPS Growth
- AS N/A
- GMAB 83.82
- EPS
- AS N/A
- GMAB 16.85
- Revenue
- AS $4,843,300,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- AS $21.01
- GMAB $18.78
- Revenue Next Year
- AS $14.98
- GMAB $14.98
- P/E Ratio
- AS N/A
- GMAB $12.94
- Revenue Growth
- AS 13.38
- GMAB 30.67
- 52 Week Low
- AS $10.11
- GMAB $18.64
- 52 Week High
- AS $34.00
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- AS 40.74
- GMAB 65.39
- Support Level
- AS $30.30
- GMAB $18.74
- Resistance Level
- AS $31.50
- GMAB $22.55
- Average True Range (ATR)
- AS 1.28
- GMAB 0.46
- MACD
- AS -0.40
- GMAB 0.39
- Stochastic Oscillator
- AS 8.88
- GMAB 94.64
About AS AMER SPORTS INC
Amer Sports manages a diverse portfolio of 10 outdoor and action sports brands that collectively generated revenue of $4.4 billion in 2023. Although primarily owned by the Chinese conglomerate Anta Sports, Amer operates with a degree of autonomy. In its rapidly expanding China business, the company is subject to closer oversight, but it manages its operations outside of China with relative independence. In 2023, the firm generates 40% of its revenue from the Americas, 33% from Europe, the Middle East, and Africa, 19% from China, and 7% from Asia-Pacific, excluding China.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.